Sunday, 18 October 2026
Sapien M3 system recall, Clinical AI governance framework, Ghana yellow fever alert
- 01
Edwards recalls Sapien M3 delivery systems after balloon failures
Edwards Lifesciences has asked customers to remove and return four lots of Commander M delivery systems used for Sapien M3 transcatheter mitral valve replacement after three reports of balloons bursting during inflation. One death and one serious injury were associated with the problem as of 5 October, according to the US Food and Drug Administration. The FDA said the failure could cause an embolism or prevent retrieval of the device through the guide sheath, potentially requiring an additional intervention such as surgery. The affected lots comprise fewer than 200 systems, while other lot numbers are unaffected and can continue to be used. Sapien M3 is intended for patients considered too frail for mitral valve repair or open heart surgery.
via MedTech Dive
- 02
AMA sets four-part governance framework for clinical AI agents
The American Medical Association has released a governance framework for the safe and effective use of AI agents performing clinical tasks. It asks what clinical function an agent performs, what evidence supports its performance and response to failure, what it may do and under which conditions, and who is accountable for risks and outcomes. The framework covers tools used in areas including ambient documentation, diagnostics and patient monitoring, with the AMA emphasising physicians’ central role in their development and deployment. In a survey of 250 US healthcare leaders, 28% reported deploying agentic AI and 44% reported pilots or proof-of-concept projects, while 72% said the tools were occasionally implemented without IT approval. The framework will guide the AMA’s work with other organisations as healthcare groups respond to rapidly expanding use and limited federal regulation.
via MedTech Dive
- 03
CDC issues Level 2 yellow fever notice for Ghana
Yellow fever risk in Ghana has prompted a Level 2 CDC travel health notice. The CDC said travellers to areas where vaccination is recommended should receive yellow fever vaccine at least 10 days before travel and prevent mosquito bites. Symptoms develop 3–6 days after infection, and about 15% of infected people develop severe illness that can cause liver disease, bleeding, shock, organ failure, jaundice and sometimes death. Diagnosis relies on symptoms, laboratory testing and travel history, and no medications treat or cure the disease.
- 04
Navepegritide backed for childhood achondroplasia treatment in Europe
The CHMP has recommended European marketing authorisation for navepegritide (Yuviwel) to treat achondroplasia in children aged 2 years and older whose epiphyses are not closed. In a 52-week randomised, double-blind, placebo-controlled trial, the injectable treatment improved annualised growth velocity by 1.49 cm compared with placebo. The most common adverse effects were injection-site reactions and hypertrichosis, including abnormal hair growth at the injection site. The proposed indication requires confirmation of achondroplasia through appropriate genetic testing, with prescribing and monitoring by physicians experienced in managing children with the condition. The European Commission must grant marketing authorisation before detailed product information is published.
- 05
CHMP backs ranibizumab biosimilar Fovlussea for retinal diseases
The CHMP adopted a positive opinion recommending EU marketing authorisation for Fovlussea, a ranibizumab biosimilar, on 15 October 2026. The proposed adult indications include wet age-related macular degeneration, diabetic macular oedema, proliferative diabetic retinopathy, macular oedema secondary to retinal vein occlusion and visual impairment due to choroidal neovascularisation. Data showed comparable quality, safety and efficacy to the reference product Lucentis. Fovlussea will be available as a 10 mg/ml solution for injection and must be administered by a qualified ophthalmologist experienced in intravitreal injections. The European Commission will decide whether to grant marketing authorisation.
- 06
Illegal markets threaten Australia’s historic decline in smoking
Australia’s historic decline in smoking could reverse amid expanding illegal tobacco and vape markets, according to former RACGP smoking cessation guideline chair Professor Nick Zwar. Daily smoking fell from about 21% when the inaugural guideline was released in 2004 to a record low of 5.6% in the latest National Drug Strategy Household Survey. Professor Zwar said illegal tobacco was overtaking legal products as the main source of combustible tobacco, while illegal vapes and nicotine pouches posed additional threats. He described the guideline’s recommendation of vaping for people who had not succeeded with approved pharmacotherapies as reasonable, but said the medical vaping model had not achieved the uptake he expected. Dr Hester Wilson has succeeded him as chair of the guideline’s Expert Advisory Group.
via RACGP newsGP
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.